Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2010

GlobeImmune Raises $17.5M in Series E Financing

  • GlobeImmune obtained $17.5 million in a Series E Preferred Stock financing. The firm is developing active immunotherapy products called Tarmogens® for cancer and infectious diseases. The round was led by new investors Generali Financial Holding and BSI SA, and existing investors also participated.

    GlobeImmune’s lead infectious disease program, GI-5005, is a potential treatment for chronic HCV infection. GI-5005 is currently being developed in combination with the current standard of care, pegylated interferon and ribavirin. Treatment-naive patients with genotype 1 HCV receiving GI-5005 and standard of care demonstrated a 15% absolute improvement in complete response rate at the end of 48 weeks of treatment relative to patients receiving standard of care alone.

    The firm’s lead oncology program, GI-4000, targets cancers caused by a mutated Ras protein. GI-4000 is currently in a randomized, active-control, adjuvant, Phase IIb trial in resected pancreatic cancer in combination with the current standard of care, gemcitabine. Phase II studies in locally advanced pancreatic cancer and non-small-cell lung cancer (NSCLC) are planned.

    Other candidates are in preclinical testing for the treatment of influenza, glioblastoma, and NSCLC. GlobeImmune is also working to discover additional anticancer agents through a partnership with Celgene inked in May 2009.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »